Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bupropion is used to treat depression during pregnancy. However, its usefulness as a smoking cessation aid for pregnant women is not fully known. OBJECTIVE: The objective of the study was to evaluate the preliminary efficacy of bupropion sustained release for smoking cessation during pregnancy. STUDY DESIGN: We conducted a randomized, prospective, double‐blind, placebo‐controlled, pilot trial. Pregnant women who smoked daily received individualized behavior counseling and were randomly assigned to a 12 week, twice‐a‐day treatment with 150 mg bupropion sustained release or placebo. The primary study objectives were to determine whether bupropion sustained release reduces nicotine withdrawal symptoms on the quit date and during the treatment period compared with placebo and whether it increases 7 day point prevalence abstinence at the end of the treatment period and at the end of pregnancy. RESULTS: Subjects in the bupropion (n = 30) and placebo (n = 35) groups were comparable in age, smoking history, number of daily smoked cigarettes, and nicotine dependence. After controlling for maternal age and race, bupropion sustained release reduced cigarette cravings (1.5 ± 1.1 vs 2.1 ± 1.2, P = .02) and total nicotine withdrawal symptoms (3.8 ± 4.3 vs 5.4 ± 5.1, P = .028) during the treatment period. Administration of bupropion sustained release reduced tobacco exposure, as determined by levels of carbon monoxide in exhaled air (7.4 ± 6.4 vs 9.1 ± 5.8, P = .053) and concentrations of cotinine in urine (348 ± 384 ng/mL vs 831 ± 727 ng/mL, P = .007) and increased overall abstinence rates during treatment (19% vs 2%, P = .003). However, there was no significant difference in 7 day point prevalence abstinence rates between the 2 groups at the end of medication treatment (17% vs 3%, P = .087) and at the end of pregnancy (10% vs 3%, P = .328). CONCLUSION: Individual smoking cessation counseling along with the twice‐daily use of 150 mg bupropion sustained release increased smoking cessation rates and reduced cravings and total nicotine withdrawal symptoms during the treatment period. However, there was no significant difference in abstinence rates between groups at the end of medication treatment and at the end of pregnancy, likely because of the small sample size. A larger study is needed to confirm these findings and to examine the potential benefit/ risk ratio of bupropion sustained release for smoking cessation during pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interventions for promoting smoking cessation during pregnancy
Lumley, J., Chamberlain, C., Dowswell, T., Oliver, S., Oakley, L., & Watson, L. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001055.pub3 · Cited by 890
ROLLNICK, S., HEATHER, N., GOLD, R., & HALL, W. (1992) · British Journal of Addiction · doi:10.1111/j.1360-0443.1992.tb02720.x · Cited by 818
Ensuring balanced distribution of prognostic factors in treatment outcome research.
Stout, R. L., Wirtz, P. W., Carbonari, J. P., & Del Boca, F. K. (1994) · Journal of Studies on Alcohol, Supplement · doi:10.15288/jsas.1994.s12.70 · Cited by 461 · cited 1×
“To ensure comparability of subjects in the treatment groups, we used the urn randomization method.(6) The groups were balanced for 2 variables: gestational age at study entry and number of CPD.”
Patnode, C. D., Henderson, J. T., Thompson, J. H., Senger, C. A., Fortmann, S. P., & Whitlock, E. P. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0171 · Cited by 238
Cited by
Pharmacological interventions for promoting smoking cessation during pregnancy
Coleman, T., Chamberlain, C., Davey, M.-A., Cooper, S. E., & Leonardi-Bee, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010078.pub2 · Cited by 357
McAllister-Williams, R. H., Baldwin, D. S., Cantwell, R., Easter, A., Gilvarry, E., Glover, V., Green, L., Gregoire, A., Howard, L. M., Jones, I., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699361 · Cited by 271
Pharmacological interventions for promoting smoking cessation during pregnancy
Claire, R., Chamberlain, C., Davey, M.-A., Cooper, S. E., Berlin, I., Leonardi-Bee, J., & Coleman, T. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010078.pub3 · Cited by 188
Hajek, P., Przulj, D., Pesola, F., Griffiths, C., Walton, R., McRobbie, H., Coleman, T., Lewis, S., Whitemore, R., Clark, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01808-0 · Cited by 85
Tran, D. T., Preen, D. B., Einarsdottir, K., Kemp-Casey, A., Randall, D., Jorm, L. R., Choi, S. K. Y., & Havard, A. (2020) · BMC Medicine · doi:10.1186/s12916-019-1472-9 · Cited by 29
Metadata
- Authors
- Nanovskaya, T. N., Oncken, C., Fokina, V. M., Feinn, R. S., Clark, S. M., West, H., Jain, S. K., Ahmed, M. S., & Hankins, G. D. V.
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 216
- Issue
- 4
- Pages
- 420.e1-420.e9
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W2550723764
- Cited by
- 35
- References
- 4
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/j.ajog.2016.11.1036
- The paper
- Nanovskaya, T. N., Oncken, C., Fokina, V. M., Feinn, R. S., Clark, S. M., West, H., Jain, S. K., Ahmed, M. S., & Hankins, G. D. V. (2017). Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2016.11.1036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.